Advertisement

U.S. FDA panel backs Aerie's glaucoma drug Rhopressa

U.S. FDA panel backs Aerie's glaucoma drug Rhopressa
From Reuters - October 13, 2017

(Reuters) - Aerie Pharmaceuticals Incs experimental glaucoma treatment should be approved, an advisory committee to the U.S. Food and Drug Administration said on Friday, after it found the benefits outweigh the risks.

The panel voted 9-1 in favor of the drug, Rhopressa, the first in a new class of treatments for glaucoma, an eye condition that is the second-leading cause of blindness in the world. It affects about 2.7 million people in the United States.

The FDA is not obliged to follow the recommendations of its advisory panels but typically does.

Advertisement

Continue reading at Reuters »